IPCA's Q2 EBITDA grew 16% YoY (6x QoQ), which was 33% ahead of our estimate. This was led by (1) strong recovery in India business (up 3% YoY/44% QoQ), (2) ~335 bps YoY improvement in gross margin with better product mix (lower anti-malaria business in India)